PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is considered one of the best medical device stocks to buy, with an analyst reiterating a Buy rating and $83 price target on August 8. The company reported a 4% sales beat in Q2, driven by international momentum and higher US prices, leading to improved full-year sales guidance and gross margin outlook.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company specializing in urology solutions. The AquaBeam Robotic System, an image-guided surgical robotic system, is used in minimally invasive urologic surgery. The company’s performance stability and growth have been highlighted by an analyst, suggesting a positive outlook for the future.

While PRCT shows investment potential, some AI stocks may offer greater upside with lower risk. A free report on the best short-term AI stock for potential benefits from Trump-era tariffs and onshoring trends is available. For more insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.”

Read more at Yahoo Finance: Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)